Back to search results

Colchicine for Inflammation After Heart Surgery

This study is looking at whether the medication colchicine (Colcrys®) can help reduce inflammation and prevent an irregular heartbeat called atrial fibrillation after coronary artery bypass graft (CABG) surgery. Adults aged 18 to 99 who are scheduled for CABG surgery can join. You would be randomly assigned to receive either colchicine or a placebo (an inactive capsule) for a short period around your surgery. The study will measure changes in inflammatory markers and the rate of atrial fibrillation to see if colchicine is effective. The current status of this study is unclear.

Study design
This is an interventional study with 24 planned participants. It is a blinded study, meaning neither you nor the study team will know if you are receiving colchicine or the placebo.
What's involved
You would start taking the study medication (colchicine or placebo) 5 days before surgery and continue for up to 10 days after surgery or until you leave the hospital. Inflammatory markers will be measured at several points before and after surgery.
Compensation
Not stated in the trial record.
Follow-up
The rate of post-operative atrial fibrillation will be monitored through hospital discharge, up to 15 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07287345

Colchicine's Effect on Inflammatory Markers

Recruiting
PHASE4Ages 18–99InterventionalTreatment
Ayesha Ather
~24 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Colchicine (Colcrys®)Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Inflammatory markers
Measured over Baseline (pre-surgery), 24, 48, 72, 96 hours post-surgery and 10 days postoperatively or at discharge, whichever occurs first.
+1 more outcome measured

Conditions

Colchicine
Inflammation in Cardiac Surgery
Post Operative Atrial Fibrillation
Inflammatory Markers
Colchicine Adverse Reaction

Explore related trials

Coronary Artery Disease

Where it's being run

1 sites across 1 states
Kentucky1

Study leadership

  • Sibu Saha, MD · STUDY_DIRECTOR · University of Kentucky

Who to contact

Ayesha Ather
[email protected]
8592184157
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years and older
Coronary artery bypass graft (CABG) planned procedure

Exclusion

History of atrial fibrillation
Off-pump CABG procedure
Current treatment with colchicine for any cause
Hypersensitivity to colchicine (as indicated by rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever)
Emergency cardiac surgery
Extracorporeal Membrane Oxygenation (ECMO) pre- or post-cardiac surgery
Heart transplant patients
Left ventricular assist device (LVAD) patients
Serum creatinine \>2.0 mg/dL
Preoperative elevated CK or known myopathy
Severe liver disease or elevation of serum transaminases (\>1.5 times the upper limit of 40 units/liter)
Chronic intestinal disease or blood dyscrasia
Unable to speak English
Pregnancy or lactation in women

What this trial measures

  • Change in Inflammatory markersBaseline (pre-surgery), 24, 48, 72, 96 hours post-surgery and 10 days postoperatively or at discharge, whichever occurs first.

    markers of inflammation (IL-6, CRP, IL-18, IL-1β, IL-8, and TNF-α) will be measured at predefined time points. Blood samples will be obtained as part of routine clinical care and analyzed using commercially available ELISA assays.

  • Rate of post-operative atrial fibrillation (POAF)Through discharge (up to 15 days)

    Postoperative atrial fibrillation (POAF) incidence will be assessed through daily chart review.